Post‐Marketing Safety of Ustekinumab Based on 14‐Year Follow‐Up in Danish National Patient Data
The present study corroborated the enduring safety of ustekinumab in the context of PsO treatment.
Authors
- Se Jun Kim (ORCID: https://orcid.org/0000-0001-7150-4685)
- Alexander Egeberg (ORCID: https://orcid.org/0000-0001-8257-1816)
- Lone Graff Stensballe (ORCID: https://orcid.org/0000-0003-1569-153X)
- Andreas Jensen (ORCID: https://orcid.org/0000-0003-4302-2982)
Institutions
- University of Copenhagen (DK)
- Bispebjerg Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1002/pds.70064
- Citations
- 3
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Amgen
- Bristol-Myers Squibb
- National Psoriasis Foundation
- Eli Lilly and Company
- Pfizer
- Mylan
- Horizon Therapeutics
- Galápagos
- Kongelig Hofbuntmager Aage Bangs Fond
- Galderma
- Simon Spies Fonden
- LEO Pharma
- Samsung
- Janssen Pharmaceuticals